Navigation Links
WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
Date:6/16/2009

SHANGHAI, June 16 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that Edward Hu, the Company's Chief Operating Officer and acting Chief Financial Officer, will present at the Third Annual Jefferies Healthcare Conference in New York on Wednesday, June 17, 2009, at 11:45 am Eastern Daylight Savings Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The Company will broadcast its presentation. The public may access the broadcast through the Investor Relations section of the Company's web site: http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017   ... Beyond Type 1, a not-for-profit advocacy and education group ... a grant from Beyond Type 1 to support ViaCyte,s ... and other insulin-requiring diabetes.  For more ... cell-derived cell replacement therapies with a focus on the ...
(Date:2/22/2017)... Feb. 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a ... of innovative biopharmaceutical products for companion animals, will host a ... a.m. ET to discuss financial results from the fourth quarter ... Interested participants and investors may access the audio webcast ... ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Park ... free AFM Luncheon for all SPIE attendees and Park customers ... just one block from the San Jose Convention Center. The luncheon will feature ...
(Date:2/22/2017)... Scientists propose in Nature blocking ... Gaucher and maybe other lysosomal storage diseases as a ... current therapies. An international research team led ... also included investigators from the University of Lübeck in ... 22. The study was conducted in mouse models of ...
Breaking Biology Technology:
(Date:1/26/2017)...  Crossmatch, a leading provider of security and identity ... combatting fraud, waste and abuse in assistance operations around ... on Disaster Relief conference in Panama City ... and foreign assistance organizations throughout Latin America ... a largely unacknowledged problem in the foreign assistance and ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... ... voice recognition biometrics market to grow at a CAGR of 19.36% ... present scenario and the growth prospects of the global voice recognition ... considers the revenue generated from the sales of voice recognition biometrics ...
Breaking Biology News(10 mins):